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Abstract. Background/Aim: Treatment options for patients
with metastatic soft tissue sarcomas are limited. Re-
challenge with a previously successful gemcitabine-based
regimen is common. There are no published data to support
this practice. Patients and Methods: We conducted a
retrospective search to identify patients re-challenged with
gemcitabine-based chemotherapy (GBC) from 2003 to 2015.
Results: Twenty-nine patients re-challenged with gemcitabine
were identified. The response rate for initial GBC was 55%
(n=15) and for re-challenge GBC 26% (n=6). The median
progression-free survival was 11.1 months (95%CI=7.2-11.9)
for initial GBC and 5.3 months (95%CI=2.0-7.5) for re-
challenge GBC. Overall survival following gemcitabine re-
challenge was 12.2 months (95%CI=7.0-18.2). Twelve out of
26 evaluable patients (46%) treated with re-challenge GBC
experienced grade 3-4 adverse events (CTCAE 4.03) with
31% (n=8) of patients requiring dose reduction. Conclusion:
In selected patients, gemcitabine re-challenge can be
considered in advanced sarcomas, however, this approach is
associated with toxicity.
Soft tissue sarcomas (STS) are rare tumours that represent
approximately 1% of adult cancers (1). STS comprise more
than 60 different entities of which leiomyosarcoma (LMS),
liposarcoma (LPS) and undifferentiated pleomorphic sarcoma
are among the most common subtypes (2). For localized
disease, surgery with or without neoadjuvant/adjuvant
radiation is the mainstay of management (3, 4). The role of
neoadjuvant/adjuvant chemotherapy is controversial, but it
may be considered in patients with high risk of relapse (5, 6).
Despite advances in therapy, approximately 50% of patients
will develop recurrent/metastatic disease. The cornerstone of
treatment for metastatic/locally advanced inoperable disease
consists of palliative systemic chemotherapy. 
Anthracycline-based therapy (either alone or in
combination) is the standard first-line therapy (7, 8). Over
the last few years, a number of new agents have been
approved for 2nd and subsequent line therapy, including
trabectedin, pazopanib and eribulin (9, 10). However, older
chemotherapy drugs such as ifosfamide and gemcitabine still
belong to the standard armamentarium for advanced disease.
Gemcitabine is a pyrimidine antimetabolite drug
frequently used in combination with docetaxel. In a phase II
trial conducted by the Sarcoma Alliance for Research
through Collaboration (SARC) in unselected metastatic STS,
the combination of gemcitabine plus docetaxel was superior
to gemcitabine alone in terms of response rate (16% vs. 8%),
median progression-free (6.2 vs. 3.0 months) and median
overall survival (17.9 vs. 11.5 months) at the expense of a
higher toxicity profile (11). The French phase II TAXOGEM
trial, evaluated gemcitabine vs. gemcitabine docetaxel as
2nd-line therapy in patients with metastatic leiomyosarcoma.
The endpoint of the study was response rate, which was 19%
for gemcitabine alone and 24% for the combination arm (not
statistically significant). The median progression-free
survival was 6.3 months for non-uterine leiomyosarcomas
treated with the combination compared to 3.8 months for the
gemcitabine monotherapy arm (12). 
Gemcitabine can also be combined with dacarbazine. In a
phase II trial conducted by the Spanish Sarcoma Group
(GEIS), gemcitabine plus dacarbazine was compared to
dacarbazine alone in previously treated STS patients. The
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combination arm yielded a higher response rate (12% vs.
4%), as well as longer progression-free (4.2 vs. 2 months;
HR=0.58; p=0.005) and overall survival (16.8 vs. 8.2
months; HR=0.55; p=0.014) (13). 
Despite the recent advances and the incorporation of new
drugs, treatment options for metastatic STS remain limited.
Consequently, maximising the existing regimens by re-
challenging selected patients who relapse after a reasonable
interval with the same effective chemotherapy agent can be
considered. Re-challenge with doxorubicin is not possible
due to the risk of cardiotoxicity. In a retrospective study,
ifosfamide re-challenge was found to be a viable option for
metastatic STS, specifically  synovial sarcoma (14). 
Gemcitabine-based re-challenge may also be an option in
selected patients previously benefitting from gemcitabine. To
our knowledge, there are no published data supporting this
strategy and therefore, the aim of this study was to evaluate
the efficacy and toxicity of gemcitabine-based re-challenge
in STS patients treated at a single referral centre. 
Materials and Methods
Institutional approval was obtained prior to commencing the study
(Royal Marsden Clinical Audit Committee approval 7/11/2017). The
prospectively maintained Royal Marsden Sarcoma Unit database was
retrospectively reviewed to identify patients re-challenged with
gemcitabine between 2003 and 2015. Gemcitabine-based re-challenge
was defined as treatment with gemcitabine as mono-therapy or in
combination with another chemotherapy agent (docetaxel or
dacarbazine) in any line and subsequent re-treatment with
gemcitabine in a further line. Initial gemcitabine-based chemotherapy
was defined as the chemotherapy line that gemcitabine was first used.
Clinical data and demographics as well as treatment details were
obtained from the electronic patient records. This study was not
limited to any specific histology and in all cases the histologic
diagnosis was confirmed by a specialist STS pathologist (KT). 
Chemotherapy schedules, response and toxicity assessment.
Gemcitabine was administered as monotherapy at 1,200 mg/m2
Days 1 and 8 every 3 weeks or in combination with docetaxel
(gemcitabine 900 mg/m2 or 675 mg/m2 Days 1 and 8 and docetaxel
75 mg/m2 Day 8) or dacarbazine (gemcitabine 1,800 mg/m2 Days
1 and 15 and dacarbazine 500 mg/m2 Days 1 and 15). Re-challenge
gemcitabine-based regimes could be the same as the first or differ
at the discretion of the treating oncologist. 
Response assessment was performed using CT scans. We
retrospectively reviewed CT scans performed every 2 to 3 cycles using
Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Re-
review of radiologic response was only possible for imaging performed
from 2006 onwards (following installation of electronic archiving). 
Cancer Institute Common Terminology Criteria for Adverse
Events (CTCAE) were used to record grade 3 and 4 toxicities.
Statistical analysis. Clinical activity to gemcitabine-based
chemotherapy (GBC) was measured following RECIST 1.1 as the
percentage of patients achieving a complete response (CR) or a
partial response (PR).
Progression-free survival (PFS) for first GBC treatment was
calculated from the first treatment date until disease progression and
for second GBC from the first treatment date until disease
progression, death by any cause or last follow-up.
Overall survival of the series was calculated from the original
diagnosis date until death by any cause or last follow up. Overall
survival (OS) after GBC re-challenge was calculated from the first
treatment date of the second GBC treatment to the date of death by
any cause or last follow-up. For OS and PFS analysis, survival
curves and survival medians were estimated at 95% confidence
using the Kaplan–Meier estimator. A 95% level of significance was
used for all the statistical tests. All statistical analyses were done
using the statistical software STATA version 13.1.
Results
Baseline characteristics. From 2003 to 2015 a total of 29
patients were re-challenged with gemcitabine-based
chemotherapy (GBC). The median age at diagnosis was 48
years and 72% of the patients were female. The majority of
patients were diagnosed with metastatic leiomyosarcoma (n=25,
86%) mostly uterine leiomyosarcoma (n=16, 55%) and the
ANTICANCER RESEARCH 39: 347-351 (2019)
348
Table I. Baseline characteristics.
                                                                        Overall patients (N=29)
                                                                                      N (%)
Age                                                                                 
   Median (range)                                                       48 (30-60)
Gender                                                                            
   Male                                                                          8 (28)
   Female                                                                    21 (72)
Primary site location                                                      
   Uterus                                                                     16 (55)
   Retroperitoneum                                                      4 (14)
   Extremities                                                               4 (14)
   Other                                                                        5 (17)
Histology                                                                        
   Leiomyosarcoma                                                    25 (86)
   Angiosarcoma                                                          1 (3.5)
   Spindle cell sarcoma                                                1 (3.5)
   Endometrial Stromal Sarcoma                                1 (3.5)
   Kaposi Sarcoma                                                       1 (3.5)
Grade                                                                              
   Low                                                                           2 (7)
   Intermediate                                                             7 (24)
   High                                                                        14 (48)
   Unknown                                                                  6 (21)
First GBC regimen                                                        
   Gemcitabine-docetaxel                                          25 (86)
   Gemcitabine monotherapy                                      4 (14)
Re-challenge GBC regimen                                          
   Gemcitabine-docetaxel                                          19 (66)
   Gemcitabine monotherapy                                      9 (31)
   Gemcitabine-DTIC                                                  1 (3)
GBC: Gemcitabine-based chemotherapy; DTIC: dacarbacine.
majority of the tumours were intermediate to high grade (n=21).
The baseline characteristics of this series are shown in Table I.
Response and toxicity 
Initial gemcitabine-based chemotherapy. Thirty-eight percent
(n=11) of patients received initial GBC as 1st-line therapy,
45% (n=13) as 2nd-line and 17% (n=5) as 3rd-line or greater.
Twenty-five (86%) patients received gemcitabine plus
docetaxel as initial GBC and the remainder gemcitabine
alone as initial GBC. The median number of cycles
administered was 5.4. Twenty-eight patients were evaluable
for response, as one patient did not have RECIST
measurable disease. The response rate was 55% (n=15).
Nine (31%) of the evaluable patients experienced grade 3-
4 toxicity and 7 (24%) required a dose reduction.
Re-challenge gemcitabine-based chemotherapy. Re-challenge
GBC consisted of gemcitabine-docetaxel in 66% (n=19),
gemcitabine mono-therapy in 31% (n=9) and gemcitabine-
dacarbazine in 3% (n=1) of patients. Re-challenge GBC was
administered as 2nd-line therapy in 21% (n=6), as 3rd-line
in 34% (n=10) and 4th-line/greater in 45% (n=13) of
patients. The median number of cycles administered was 4.2.
Twenty-three patients were evaluable for response and the
response rate for gemcitabine re-challenge was 26% (n=6). 
Twelve out of 26 patients (46%) treated with re-challenge
GBC experienced grade 3-4 adverse events and 31% (n=8)
required a dose reduction. 
Only patients with leiomyosarcoma had RECIST
radiological responses (n=15/25) to either initial or re-
challenge GBC. No radiological responses were observed in
the 4 other histological subtypes. A total of 5 patients had a
response to initial GBC and also to gemcitabine re-challenge.
Progression-free and overall survival. The median PFS was
11.1 months (95%CI=7.2-11.9) for initial GBC. For re-
challenge with gemcitabine-based chemotherapy median PFS
was 5.3 months (95%CI=2.0-7.5) (Figure 1). 
Following initial GBC, the majority of patients (n=23) had a
PFS of more than 6 months. Two of the patients not achieving
6 months PFS had angiosarcoma and spindle cell sarcoma.
Following re-challenge GBC, a total of 16 patients had a
PFS longer than 4 months. 
The median overall survival from sarcoma diagnosis of
this series was 50.6 months (95%CI=33.4-69.9). The median
overall survival for patients treated with gemcitabine re-
challenge was 12.2 months (95%CI=7.0-18.2) (Figure 1).
Discussion
Our retrospective study suggests that re-challenge with a
previously successful gemcitabine-based regimen can be a
therapeutic option for selected metastatic soft tissue sarcoma
patients. 
It is important to highlight that in our clinical practice we
selected patients achieving a good and prolonged response
with initial GBC before considering re-challenge with
gemcitabine. Furthermore, we would not employ re-
challenge GBC in those with progressive disease to initial
GBC and those with a poor performance status.
In our study, the majority of patients had leiomyosarcoma
(mostly grade 2 and 3) highlighting the higher sensitivity of
this subtype to gemcitabine-based chemotherapy (15). 
The majority of patients were treated with gemcitabine
plus docetaxel as initial (55%) and re-challenge (25%) GBC. 
The median PFS for initial GBC was 11.1 months, which
is longer than that reported in prospective trials. This is
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Figure 1. Progression-free survival following initial and re-challenge gemcitabine-based chemotherapy. a) Progression-free survival following initial
gemcitabine-based chemotherapy. b) Progression-free survival following re-challenge gemcitabine-based chemotherapy.
probably due to the inherent selection bias of this series (i.e.
to be considered for re-challenge, patients had durable
benefit to initial GBC). In the GeDDis trial, comparing 1st-
line gemcitabine-docetaxel versus doxorubicin, the median
PFS for gemcitabine-docetaxel was 6 months. The median
PFS for re-challenge GBC was relatively long (5.3 months),
considering many patients received re-challenge GBC as 4th-
line or greater. Moreover, the median overall survival
following re-challenge GBC was 12.2 months, but again this
emphasises the selection of this chemo-sensitive cohort.
Gemcitabine plus docetaxel is associated with
considerable toxicity. In the phase II trial published in 2002,
the haematological grade 3-4 toxicities were 21%
neutropenia (neutropenic fever 6%), 29% thrombocytopenia
and 15% anaemia, and non-haematological grade 3-4
toxicities included 21% dyspnoea or 21% fatigue (16). In the
phase III GeDDis trial, 285 serious adverse events were
reported of which 111 (39%) were febrile neutropenia, fever
and neutropenia, which led to 18% dose reductions (8).
Other gemcitabine combinations or gemcitabine
monotherapy have been associated with a lower percentage
of severe adverse events (12, 13), but in our study fewer
patients were treated with these regimens. Grade 3-4
toxicities in the re-challenge GBC setting were high (46%)
and a considerable number of patients needed a dose
reduction (31%). The fact that patients were treated in the
4th-line or greater may have contributed to this toxicity
profile (i.e. heavily pre-treated). Therefore, when considering
gemcitabine re-challenge the risk of increased toxicity should
be discussed carefully with patients. If toxicity is a potential
concern, then gemcitabine mono-therapy could be used. 
The limitations of our study include its retrospective
nature, the small number of patients, the lack of radiological
review for some patients as well as the lack of patient
reported outcome measures (which are particularly relevant
in the setting of pre-treated advanced cancer). 
Conclusion
The outcome of patients with metastatic soft tissue sarcoma
remains poor with few systemic therapy options. Gemcitabine
re-challenge could be a potential option for selected patients.
Based on our results, patients with leiomyosarcoma achieving
a PFS longer than 6 months following initial GBC could
benefit the most. However, it is important to discuss the
potential for toxicity carefully with patients, particularly if re-
challenge is offered to heavily pre-treated patients. 
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